Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares JPMorgan USD Emerging Markets Bond ETF (EMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares JPMorgan USD Emerging Markets Bond ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $286.92 (market cap $39.89B), while iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.48. The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | EMB | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Fixed Income |
52-Week High | $491.22 | $97.74 |
52-Week Low | $278.09 | $91.52 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
EMB trades at $95.99, showing minimal daily movement with a 0.03% gain. Technical indicators signal a bearish trend, while oscillators remain neutral. Recent corporate actions include scheduled dividend payments for mid-2026. News coverage highlights emerging market bond risks and Federal Reserve policy impacts on performance.
The outlook for EMB is cautious due to emerging market sovereign default risks and interest rate sensitivity. Investment opportunity lies in its yield for income-focused investors, but macroeconomic volatility and geopolitical tensions present significant headwinds for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →
